The ever popular 5-α-reductase inhibitors that minimize symptoms of BPH while both reducing overall prostate cancer incidence and obscuring early diagnosis have a new indication to tout: reducing the risk of bladder cancer progression. In a huge Korean cohort study of over 22K men with bladder cancer, the 5300 men with pre-existing 5-α-reductase inhibitor prescriptions for at least one year had lower risk of subsequent radical cystectomy (HR 0.74) and mortality (HR 0.83) when compared to propensity-matched counterparts. The thought is these agents impede well-established androgen-mediated bladder carcinogenesis. | An, JAMA Netw Open 2023
